Breaking News, Financial News

Financial Report: Hospira 1Q

Growth in the quarter was driven by the Specialty Injectable Pharmaceuticals segment, with strong U.S. sales of the generic oncolytic oxaliplatin and Precedex, Hospira's proprietary sedation agent.

Hospira 1Q10

1Q Revenues:
$1.0 billion (+17%)

1Q Earnings:
$141.7 million (-14%)

Comments: Growth in the quarter was driven by the Specialty Injectable Pharmaceuticals segment, with strong U.S. sales of the generic oncolytic oxaliplatin and Precedex, Hospira’s proprietary sedation agent. Global Specialty Injectables revenue was $611.4 million in the quarter, up 42%. In the Americas, revenue was $483.9 million (+45%). In Europe, Middle East & Africa sales were $69.9 million (+21%). In Asia Pacific sales were 57.6 million (+48%). Contract manufacturing revenues are not broken out.

Click here to learn more about Hospira.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters